Literature DB >> 31686868

Association of diabetes mellitus with hepatitis B and hepatitis C virus infection: evidence from an epidemiological study.

Yujia Liu1, Shangyuan Ye2, Xianchao Xiao1, Tong Zhou1, Shuo Yang1, Gang Wang1, Chenglin Sun1, Bo Zhang2, Guixia Wang1.   

Abstract

OBJECTIVE: To study the association between glucose metabolism disorders and hepatotropic virus infection.
METHODS: A cross-sectional analysis was performed using data from the REACTION study (Risk Evaluation of Cancers in Chinese Diabetic Individuals: A Longitudinal Study). Outcomes of the analysis were test results of kidney function, liver function, lipid metabolism, and the prevalence of hepatitis B virus (HBV) infection and potential hepatitis C virus (HCV) infection (positive hepatitis C virus antibody) among individuals with and without diabetes mellitus (DM) or pre-diabetes mellitus (pre-DM).
RESULTS: Of the 10,080 patients who participated in the study, 7665 eligible subjects were included in the analysis. There was no significant difference in the prevalence of HBV infection between DM and normal subjects, pre-DM and normal subjects, and DM or pre-DM and normal subjects (p-values of 0.9180, 0.8154, and 0.6448, respectively). There was also no significant difference in the prevalence of potential HCV infection between DM and normal subjects, pre-DM and normal subjects, and DM or pre-DM and normal subjects (p-values of 0.1190, 0.0591, and 0.5591, respectively). Lipid metabolism showed a significant difference between DM or pre-DM subjects and normal subjects (p-values were less than 0.0221 in all cases). Multiple logistic regression analysis revealed hypertension as the leading significant variable associated with DM, pre-DM, and both. Other significant factors included gender, body mass index, age, and alanine aminotransferase.
CONCLUSION: No significant association was detected between DM or pre-DM and HBV or potential HCV infection. Significant association was detected between lipid metabolism disorders and DM, but this association was absent in pre-DM patients when adjusting for other factors.
© 2019 Liu et al.

Entities:  

Keywords:  diabetes; hepatitis B; hepatitis C; lipid metabolism disorder; pre-diabetes

Year:  2019        PMID: 31686868      PMCID: PMC6751765          DOI: 10.2147/IDR.S218536

Source DB:  PubMed          Journal:  Infect Drug Resist        ISSN: 1178-6973            Impact factor:   4.003


  30 in total

Review 1.  Hepatitis C virus infection and insulin resistance.

Authors:  Sandip K Bose; Ranjit Ray
Journal:  World J Diabetes       Date:  2014-02-15

2.  Insulin signalling and the regulation of glucose and lipid metabolism.

Authors:  A R Saltiel; C R Kahn
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

Review 3.  Hepatitis C virus induced insulin resistance impairs response to anti viral therapy.

Authors:  Abdel-Rahman El-Zayadi; Mahmoud Anis
Journal:  World J Gastroenterol       Date:  2012-01-21       Impact factor: 5.742

4.  Low prevalence of hepatitis-C viral seropositivity among patients with type-2 diabetes mellitus in a tertiary hospital.

Authors:  Williams Onabumeh Balogun; Jokotade Oluremilekun Adeleye; Kehinde Simeon Akinlade; Modupe Kuti; Jesse Abiodun Otegbayo
Journal:  J Natl Med Assoc       Date:  2006-11       Impact factor: 1.798

Review 5.  Epidemiology of hepatitis B and C viruses: a global overview.

Authors:  Helen S Te; Donald M Jensen
Journal:  Clin Liver Dis       Date:  2010-02       Impact factor: 6.126

Review 6.  The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence.

Authors:  Hashem B El-Serag; Howard Hampel; Fariba Javadi
Journal:  Clin Gastroenterol Hepatol       Date:  2006-03       Impact factor: 11.382

7.  Association of diabetes mellitus and chronic hepatitis C virus infection.

Authors:  A L Mason; J Y Lau; N Hoang; K Qian; G J Alexander; L Xu; L Guo; S Jacob; F G Regenstein; R Zimmerman; J E Everhart; C Wasserfall; N K Maclaren; R P Perrillo
Journal:  Hepatology       Date:  1999-02       Impact factor: 17.425

Review 8.  Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review.

Authors:  Anne-Claire Desbois; Patrice Cacoub
Journal:  World J Gastroenterol       Date:  2017-03-07       Impact factor: 5.742

Review 9.  Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution.

Authors:  Yu Zhang; Li-Min Chen; Miao He
Journal:  Virol J       Date:  2017-02-23       Impact factor: 4.099

Review 10.  Diabetes and Hepatitis C: A Two-Way Association.

Authors:  Sara Salehi Hammerstad; Shira Frankel Grock; Hanna J Lee; Alia Hasham; Nina Sundaram; Yaron Tomer
Journal:  Front Endocrinol (Lausanne)       Date:  2015-09-14       Impact factor: 5.555

View more
  4 in total

1.  Molecular evaluation of hepatitis B virus infection and predominant mutations of pre-core, basal core promoter and S regions in an Iranian population with type 2 diabetes mellitus: a case-control study.

Authors:  Fatemeh Farshadpour; Reza Taherkhani; Fatemeh Saberi
Journal:  BMC Infect Dis       Date:  2022-06-17       Impact factor: 3.667

Review 2.  Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis.

Authors:  Chien-Yu Lin; Pratik Adhikary; Kun Cheng
Journal:  Adv Drug Deliv Rev       Date:  2021-04-20       Impact factor: 17.873

3.  Non-autoimmune diabetes mellitus and the risk of virus infections: a systematic review and meta-analysis of case-control and cohort studies.

Authors:  Eric Lontchi-Yimagou; Charly Feutseu; Sebastien Kenmoe; Alexandra Lindsey Djomkam Zune; Solange Fai Kinyuy Ekali; Jean Louis Nguewa; Siméon Pierre Choukem; Jean Claude Mbanya; Jean Francois Gautier; Eugene Sobngwi
Journal:  Sci Rep       Date:  2021-04-26       Impact factor: 4.379

4.  Significantly Decreased Islet β Cell Function is Closely Associated with Hyperglycemia in Chronic Hepatitis B Patients.

Authors:  Dafeng Liu; Lingyun Zhou; Xinyi Zhang; Yilan Zeng; Lang Bai; Dongbo Wu; Hong Tang
Journal:  Int J Endocrinol       Date:  2021-08-24       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.